Clinical trials: Hot Flushes
Menopause
Efficacy and Safety of Estradiol and Progesterone Microspheres for the Treatment of Climacteric Symptoms.
During menopause a woman's body slowly produces less of the hormones estrogen and progesterone. Lower hormone levels in menopause may lead to hot flashes, vaginal dryness and osteoporosis.
- Trial name
- NCT00775242
- Testing
- Estradiol and Progesterone
- Where
- Mexico
- Volunteers
- 103 people
- Sponsor
- Centro A.F. de Estudios Tecnologicos, S.A.
Hot Flashes
A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause
This study is for women in India who are going through menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS).
- Trial name
- NCT07829653
- Testing
- Fezolinetant
- Volunteers
- 100 people
- Sponsor
- Astellas Pharma Inc
Hot Flashes
Efficacy and Safety Study in Postmenopausal Women to Determine the Lowest Effective Dose for Relief of Moderate to Severe Hot-Flushes
To determine the lowest effective dose of estradiol by comparing E2/LNG (2.2mg/0.69mg) and E2 (1.0mg) dose with placebo in decreasing the frequency and severity of moderate to severe hot flushes in postmenopausal women
- Trial name
- NCT00206622
- Testing
- Climara PRO (Estradiol / Levonorgestrel transdermal), Menostar (Estradiol transdermal)
- Where
- 45 sites in United States
- Volunteers
- 425 people
- Sponsor
- Bayer
Vasomotor Symptoms (VMS)
Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.
- Trial name
- NCT04080297
- Testing
- oral capsule of Q-122
- Volunteers
- 21 people
- Sponsor
- Que Oncology
Menopausal Hot Flushes
Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating
Sage tablets ( 3400 mg extract from fresh sage leaves, DER 1:17) in a once daily application over 12 treatment weeks are compared against placebo in 200 menopausal patients with ≥ 5 hot flushes daily and a Hyperhidrosis Scale…
- Trial name
- NCT02032862
- Testing
- Sage extract, 3400 mg , DER 1:17
- Where
- Switzerland
- Volunteers
- 107 people
- Sponsor
- A. Vogel AG
Prostate Cancer
A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients
This is a study to compare the efficacy and safety of 3 doses of DR-2031 to placebo when used as "add-on" therapy for prostate cancer patients with hot flashes following surgical or medical castration.
- Trial name
- NCT00196339
- Testing
- Cyproterone acetate 5, Cyproterone acetate 15, Cyproterone acetate 25
- Where
- 118 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- Duramed Research
Postmenopausal Women With Moderate Vasomotor Symptoms
Clinical Trial to Evaluate the Efficacy of FITOGYN Versus Placebo on the Vasomotor Symptomatology Associated With Menopause
The purpose of this study is to evaluate the efficacy of FITOGYN vs. placebo on the vasomotor symptomatology associated with menopause, to evaluate the symptoms of anxiety, the metabolic parameters in menopause and to evaluate…
- Trial name
- TRYSEM (NCT01116310)
- Testing
- Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)
- Where
- 20 sites in Spain
- Volunteers
- 166 people
- Sponsor
- Laboratorios Casen-Fleet S.L.U.
Hot Flashes
Eight-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms Associated With Menopause
This is an exploratory 8-week, multicenter, double-blind, randomized, placebo-controlled study of Brisdelle (paroxetine mesylate) Capsules 7.5 mgin subjects with moderate to severe postmenopausal vasomotor symptoms (VMS), defined…
- Trial name
- NCT00786188
- Testing
- Brisdelle (paroxetine mesylate), Sugar pill
- Where
- 10 sites in United States
- Volunteers
- 102 people
- Sponsor
- Noven Therapeutics
Hot Flashes, Sleep Disorders
Study Evaluating Totelle® in Menopausal Symptoms and Sexual Function
To evaluate the tolerability, bleeding patterns and acceptability of Totelle® 1mg administered to a population of Brazilian women in a continuous combined regime for hormone replacement therapy.
- Trial name
- NCT00195520
- Testing
- Totelle®
- Where
- 2 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years
Researchers are looking for a better way to treat men and women with vasomotor symptoms, a condition of having hot flashes caused by hormonal changes.
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
- Trial name
- NCT05381142
- Testing
- Elinzanetant (BAY3427080)
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Menopause Syndrome, Menopause
A Study of NOE-115 in Women With Vasomotor Symptoms Due to Menopause
The purpose of this study is to determine the safety, tolerability, and preliminary effectiveness of NOE-115 on moderate to severe vasomotor symptoms (hot flashes) due to menopause in women.
- Conditions
- Menopause Syndrome, Menopause, Hot Flashes
- Trial name
- NCT06385795
- Testing
- NOE-115
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Noema Pharma AG
Hot Flashes
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Japanese Women Going Through Menopause
Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes.
- Trial name
- Starlight 2 (NCT06206408)
- Testing
- Fezolinetant
- Where
- 64 sites in Japan
- Volunteers
- 410 people
- Sponsor
- Astellas Pharma Inc
Postmenopause
Study Assessing the Effects on Endometrium and Breast of Isoflavone in Post Menopausal Women
The main objective of this study is to determine the effects on the endometrium and breast of 70 mg daily dose of isoflavones.
- Trial name
- NCT00235924
- Testing
- soy isoflavone
- Volunteers
- 300 people
- Sponsor
- Laboratoires Arkopharma
Hot Flashes, Fatty Acids
Hot Flashes and Omega 3
The main objective is to evaluate the effects of omega-3 fatty acids on hot flashes frequency.
- Conditions
- Hot Flashes, Fatty Acids, Menopause
- Trial name
- BOOM3 (NCT02062528)
- Testing
- omega-3 fatty acids
- Where
- France
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Vivatech
Hot Flashes
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause
Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes.
- Trial name
- NCT06812754
- Testing
- Fezolinetant
- Where
- 26 sites in China
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Hot Flashes
A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Skylight 4 (NCT04003389)
- Testing
- fezolinetant
- Where
- 182 sites in United States, Canada and 6 more
- Volunteers
- 1,831 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Hot Flashes
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause
- Trial name
- NCT01101841
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- 32 sites in United States
- Volunteers
- 570 people
- Sponsor
- Noven Therapeutics
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults
Researchers are looking for a better way to treat people who have vasomotor symptoms (VMS). VMS such as hot flashes are caused by hormonal changes occurring during menopausal transition when women may have also changes in their…
- Trial name
- NCT05061563
- Testing
- Elinzanetant (BAY3427080), Esomeprazole
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Hot Flushes
E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)
This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.
- Trial name
- NCT02834312
- Testing
- Estetrol
- Where
- Belgium
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Donesta Bioscience
Vasomotor Symptoms; Hot Flashes
Study of Erenumab (AMG 334) in Women With Hot Flashes
The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.
- Trial name
- NCT01890109
- Testing
- Erenumab
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Amgen